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Abstract
Background: Pattern recognition receptors (PRRs) for double-stranded RNA (dsRNA) are components of innate
immunity that recognize the presence of viral infection and initiate efficient defense mechanisms. In addition to
previously well-characterized signaling pathways that are mediated by PKR and TLR3, new intracellular dsRNA
sensors, that are members of CARD and DExD/H box helicase family, have been identified. However, the molecular
mechanisms involved in the signaling pathways mediated by these new dsRNA sensors have not been extensively
characterized.
Results: Here, we studied an intracellular dsRNA pathway in the human fibrosarcoma cell line HT1080, which is
distinct from the TLR3-mediated extracellular dsRNA pathway. Particularly, the NF-kB subunits RELA and RELB were
differentially utilized by these two dsRNA signaling pathways. In TLR3-mediated dsRNA signaling, siRNA knock-
down studies suggested a limited role for RELA on regulation of interferon beta and other cytokines whereas RELB
appeared to have a negative regulatory role. By contrast, intracellular dsRNA signaling was dependent on RELA, but
not RELB.
Conclusions: Our study suggests that extracellular and intracellular dsRNA signaling pathways may utilize different
NF-kB members, and particularly the differential utilization of RELB may be a key mechanism for powerful
inductions of NF-kB regulated genes in the intracellular dsRNA signaling pathway.
Background
Pattern recognition receptors (PRRs) are key players in
host innate immune response against microbial patho-
gens. In order to launch effective defense mechanisms in
response to viral infections, a number of cellular sensors
that recognize universal components common to many
viruses have been characterized. Double-stranded RNA
(dsRNA) is one of the components that mammalian cells
have developed several different receptors for since most
viruses produce dsRNA during replication [1-3].
Interferon-inducible double-stranded RNA activated
protein kinase (PKR) has long been studied as an intra-
cellular sensor for viral dsRNA. PKR was initially charac-
terized to participate in the mechanism that shuts down
cellular translation to suppress viral replication and is
now believed to be involved in a wide range of other cel-
lular responses to viral infection [4]. Toll-like receptor 3
(TLR3) has been considered to be essential for mediating
N F - k B - i n d u c i b l eg e n er e s p o nses to polyIC, a synthetic
analogue of viral dsRNA [5], but there has yet been any
strong evidence of physical interaction between TLR3
and viral dsRNA. The precise cellular location of TLR3 is
still under discussion, but generally it is thought to be
cell type dependent. TLR3 is expressed on the cell surface
of fibroblast, but in two subtypes of dendritic cells it is
thought to be located in endosomal compartments and
transported to cell surface upon polyIC stimulation [6].
However, the role of TLR3 in innate immunity was soon
questioned when TLR3 knock-out mice had no signifi-
cant defect against virus challenges [7,8]. More recently,
Retinoic acid inducible gene I (RIG-I) and Melanoma dif-
ferentiation-associated gene 5 (MDA5), both RNA heli-
cases, were reported to be novel and important
intracellular regulators of polyIC-mediated signaling
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Embryonic fibroblasts from RIG-I knock-out mice
showed substantial defects in activation of NF-kB induci-
ble genes participating in immune defense [11]. Subse-
quent studies have indicated cell type specific
involvements of these dsRNA receptors [11,12].
Until the novel function of these RNA helicases, RIG-I
and MDA5, was discovered, a dogma of dsRNA
mediated signaling has been a separated or integrated
signaling pathway between TLR3-dependent extracellu-
lar recognition of viral dsRNA and PKR-mediated intra-
cellular recognition of viral dsRNA. Particularly in the
TLR3-PKR integrated model [13], the recognition of
viral dsRNA by TLR3 activates signaling cascades that
include PKR, leading to the activation of NF-kB and
Interferon regulatory factor 3 (IRF3). As a result, inter-
feron genes are induced by synergy between NF-kB and
IRF3, and other NF-kB-inducible inflammatory genes
are also activated. PKR is believed to initiate a similar
signaling pathway somewhere downstream because PKR
could function as an internal receptor for dsRNA as
well as a second messenger in TLR3 pathway. Therefore,
whether these two pathways are indeed integrated or
separated, TLR3-mediated signaling pathway has been
considered to be a key route of anti-viral responses.
However, according to the recent studies, RIG-I/MDA5-
mediated signaling pathways seem to be not only TLR3-
independent but also quite distinct from TLR3 pathway
in terms of participating downstream molecules
[9,10,14-18]. Although these findings imply that there
are more than one dsRNA signaling pathway, the
mechanism of action for additional intracellular (i.e.
RIG-I/MDA5 dependent) pathways is not yet clear.
A number of signaling pathways in innate immunity
eventually lead to the activation of NF-kB because its
activation is critical for the induction of many key genes
in host defense systems. So far, five members of NF-kB
family have been identified: NF-kB1 (p50/p105), NF-kB2
(p52/p100), c-REL, RELA (p65) and RELB (I-REL). A
functionally active NF-kB transcription factor consists of
homodimers or heterodimers of NF-kB members. The
p50/p65 heterodimer represents the proto-typical NF-kB
factor although a number of different combinations of
functional dimers are possible. The primary mechanism
by which NF-kB activity is regulated involves pre-
existing NF-kB dimers that are sequestered in cytoplasm
and held inactive by inhibitor proteins such as Inhibitor
of kB (IkB)-1 and -2 [19,20]. When appropriate signaling
cascades are activated, phosphorylation of inhibitor
molecules by upstream kinases leads to the dissociation
and degradation of the inhibitors through a ubiquitina-
tion pathway, and the released and activated NF-kB
dimers can then translocate into nucleus to function as
transcriptional regulators [19,20]. Although NF-kB has
been extensively studied, the differential role and utiliza-
tion of each member is not fully understood due to its
complex nature and the inherent variations in cell types
and in signaling cascades used in different studies.
In this study, we show that there are two distinct
dsRNA signaling pathways exist and that these pathways
utilize different signaling molecules, particularly NF-kB
RELA and RELB. We also propose that the utilization of
RELB may be the key mechanism of powerful induction
of IFNB and other inflammatory genes in response to
intracellular dsRNA.
Results
Differential cellular responses to extracellular and
intracellular polyIC treatments
The human fibrosarcoma cell line, HT1080, has been
extensively used as a model for studying IFN signaling
[21]. It is known to respond to dsRNA [22] and express
functional TLR3 [23]. Given recent interest in intracellu-
lar dsRNA-sensing mechanisms, we studied the
responses of HT1080 cells to extracellular stimulation
by polyIC, via addition to the culture medium, as com-
pared to intracellular stimulation, by transfection of the
polyIC. Steady-state mRNA levels of IFNB, representing
the prototypical response gene for dsRNA sensing, were
measured using quantitative real-time PCR (qPCR). A
robust induction of IFNB was observed at 40 μg/ml of
extracellular polyIC (ex-polyIC), but interestingly
HT1080 cells exhibited significantly greater sensitivity to
intracellular stimulation by polyIC transfection as the
dose response curve was shifted by more than two
orders of magnitude (data not shown). Specifically, 0.4
μg/ml of intracellular polyIC (in-polyIC) treatment
induced even greater IFNB steady-state mRNA expres-
sion levels than 40 μg/ml of ex-polyIC treatment. From
this basic observation, we were interested to determine
whether these two forms of dsRNA sensing were simply
quantitatively different or qualitatively distinct in their
mechanisms of regulation and biological functions.
We studied the kinetics of responses in HT1080 cells
to extracellular vs. intracellular dsRNA for several
known NF-kB-dependent genes (IL6, IL8, TNF, CCL2
and CCL3) along with IFNB. HT1080 cells were treated
with 40 μg/ml ex-polyIC or 0.4 μg/ml in-polyIC for 0, 2,
4, 6, 8, 10 and 12 hours, and the mRNA levels of these
genes were measured using qPCR. We observed three
distinct expression patterns among these genes in
response to ex-polyIC and in-polyIC. IFNB exemplified
one pattern in which ex-polyIC resulted in a short
phase of elevated mRNA accumulation, peaking at
2h o u r s( F i g u r e1 A )f o l l o w e db yaw e l l - d o c u m e n t e d
down-regulation phase [24], whereas in-polyIC led to
both a substantively increased magnitude of induction
and an extended period of elevated mRNA steady-state
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Figure 1 Extracellular and intracellular polyIC treatments induce genes with different kinetic and magnitude. HT1080 cell line was
treated with 40 μg/ml ex-polyIC (open square) and 0.4 μg/ml in-polyIC (closed square) for 0 to 12 hours. Gene expression was measured using
qPCR and the mean from triplicate experiments was calculated. Error bars represent standard error. A. IFNB, TNF and IL8 inductions in response
to extracellular and intracellular polyIC treatments have both different kinetic and magnitude. B. IL6 and CCL2 inductions in response to
extracellular and intracellular polyIC treatments have similar magnitude but different kinetic. C. CCL3 inductions in response to extracellular and
intracellular polyIC treatments have similar kinetic but different magnitude.
Yun et al. BMC Immunology 2011, 12:15
http://www.biomedcentral.com/1471-2172/12/15
Page 3 of 13levels, for at least up to 12 hours (Figure 1A). This
pattern was similarly observed for TNF and IL-8
(Figure 1A). Alternately, a second group of genes, exem-
plified by IL-6 and CCL2 (Figure 1B), exhibited similar
kinetics to the first pattern in response to intracellular
and extracellular polyIC stimulations with a moderate
(~5-10 fold) and sustained induction over 12 hours.
CCL3 expression represented a third pattern with simi-
lar kinetics of mRNA level inductions between
ex-polyIC and in-polyIC stimulation, that was slow and
progressive, but in which in-polyIC provided a higher
magnitude of accumulation than ex-polyIC (Figure 1C).
The substantive magnitude and extended period of
gene inductions by polyIC has been shown to involve
positive feedback loops. While it is known that auto-
crine IFN production provides a positive feedback loop
for ex-polyIC and some viruses, it is yet unclear whether
autocrine IFNs may play a similar role for in-polyIC.
Unless negative feedback mechanisms are activated, the
cellular signals initiated by these genes can be amplified.
Therefore, we studied the effect of cycloheximide, which
blocks new protein synthesis, on mRNA level inductions
in response to ex-polyIC and in-polyIC stimulation.
HT1080 cells were treated with 40 μg/ml ex-polyIC or
0.4 μg/ml in-polyIC for 8 hours in the absence/presence
of 10 μg/ml cycloheximide. The substantive induction of
these genes by in-polyIC was diminished when new pro-
tein synthesis was blocked whereas gene inductions in
response to ex-polyIC stimulation were relatively not
inhibited (Figure 2). These findings suggest that distinct
regulatory mechanisms govern intracellular vs. extracel-
lular dsRNA sensing in HT1080 cells.
Differential induction of anti-viral activity by extracellular
and intracellular polyIC
We were particularly interested in the substantive
induction of IFNB in response to a relatively small input
of in-polyIC. To examine the biological significance of
this response, we assessed the antiviral activity induced
by in-polyIC as compared to ex-polyIC treatment
(Figure 3). HT1080 cells were pre-treated with ex-
polyIC or in-polyIC for 7 hours and then challenged
with encephalomyocarditis virus (EMCV) for 30 hours
or vesicular stomatitis virus (VSV) for 40 hours with a
wide range of Multiplicity of Infections (MOIs). Under
these conditions, the observed median Tissue Culture
Infectious Dose (TCID50)f o rE M C Va n dV S Vw a s
approximately MOI = 0.01-0.03. Whereas extracellular
stimulation with 0.4 μg/ml polyIC was essentially inef-
fective, transfection with the same amount of polyIC
provided near complete protection against viral chal-
lenge extending up to MOI = 1. This represented a
comparable level of antiviral protection to that provided
by treatment with 100 U/ml of recombinant IFN-alpha.
Curiously, while 40 μg/ml ex-polyIC was ineffective in
conferring protection against EMCV, some antiviral
activity against VSV was observed although still less
than that induced by in-polyIC 0.4 μg/ml. These results
indicate that the substantive stimulation of IFNB expres-
sion by in-polyIC is associated with significant antiviral
protection although the precise proportions which are
IFNB-dependent or -independent is still unclear.
Downstream mediators of extracellular and intracellular
polyIC signaling pathways
TLR3 represents the prototypical extracellular dsRNA
sensor, although its intracellular localization in specific
Ex-polyIC
CCL2 CCL3 IL6 IL8 TNF IFNB
0
5
10
15
Control
Cycloheximide
30
40
50
60
F
o
l
d
 
I
n
d
u
c
t
i
o
n
In-polyIC
CCL2 CCL3 IL6 IL8 TNF IFNB
0
10
20
Control
Cycloheximide
200
700
1200
6000
7000
8000
F
o
l
d
 
I
n
d
u
c
t
i
o
n
Figure 2 Blocking protein synthesis diminishes substantial
gene inductions by in-polyIC stimulation. HT1080 cell line was
treated with 40 μg/ml ex-polyIC and 0.4 μg/ml in-polyIC for 8 hours
in the presence/absence of 10 μg/ml cycloheximide. Gene
expression was measured using qPCR and the mean from triplicate
experiments was calculated. Error bars represent standard error.
Gene inductions in response to ex-polyIC are not significantly
affected by cycloheximide treatment whereas gene inductions in
response to in-polyIC are diminished by cycloheximide treatment.
Yun et al. BMC Immunology 2011, 12:15
http://www.biomedcentral.com/1471-2172/12/15
Page 4 of 13cell types has also been reported [6,25]. While functional
TLR3 in HT1080 cells has been reported [23], we veri-
fied its function as a dsRNA sensor in this cell line
using TLR3 specific siRNA. Knock-down efficiency of
~75% was achieved for TLR3 using siRNA nucleofection
(Figure 4A). The induction of most genes (IFNB, IL6,
IL8, TNF, CCL2 and CCL3) in response to ex-polyIC
(40 μg/ml for 8 h) was decreased when TLR3 was
knocked down whereas the induction of the same genes
in response to in-polyIC (0.4 μg/ml for 8 h) was not sig-
nificantly affected, represented by IL8, CCL3 and IFNB
(Figure 4B). Similar experiments with 2 and 6 hour
treatments showed similar results (data not shown).
We also took advantage of the human embryonic kid-
ney 293 (HEK293) cell line, which is known to lack
functional TLR3 expression [5], in order to examine
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Figure 3 In-polyIC treatment induces effective antiviral protection. HT1080 cells were challenged with virus after various pre-treatments
including extracellular and intracellular polyIC for 7 hours. IFNA2A treatment was a positive control to show that biologically significant
interferon pre-treatment protects cells against virus. Fu-gene (transfection reagent) and 0.4 μg/ml of ex-polyIC were negative controls to show
neither of them alone elicits anti-viral protection. Cell viability was measured with crystal violet staining that shows live cells in purple. A. HT1080
cells were challenged with a serial dilution (from MOI 1 to 0.001) of encephalomyocarditis virus (EMCV). B. Summary of Figure 3A. Amount of
input EMCV virus (MOI) that causes 50% (or greater) cell survival across different polyIC treatments. C. HT1080 cells were challenged with a serial
dilution (from MOI 1 to 0.001) of vesicular stomatitis virus (VSV). D. Summary of Figure 3C. Amount of input VSV virus (MOI) that causes 50% (or
greater) cell survival across different polyIC treatments.
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Page 5 of 13intracellular dsRNA signaling. As expected, no response
for IFNB was observed when HEK293 cells were stimu-
lated with up to 40 μg/ml ex-polyIC but 15-fold induc-
tion of IFNB was detected following transfection with
0.4 μg/ml in-polyIC (supplemental data 1).
Involvement of IKK-2 in extracellular and intracellular
polyIC signaling pathways
IKK-2 is believed to play a central role in activating NF-
kB as a result of TLR3 activation [3]. Since the
in-polyIC signaling pathway seems to be TLR3 indepen-
dent, the involvement of IKK-2 was studied in HT1080
cells using an inhibitor, IKK-2 inhibitor IV (Calbio-
c h e m ) .I F N B ,I L 6 ,I L 8 ,T N F ,C C L 2a n dC C L 3m R N A
levels were measured in response to ex-polyIC (40 μg/
ml for 4 h and 8 h) or in-polyIC (0.4 μg/ml for 4 h and
8 h) in the presence of 5 μM IKK-2 inhibitor IV. Induc-
tion of IFNB and IL8 by ex-poly IC was diminished by
IKK-2 inhibitor IV, but the induction of these genes by
in-polyIC was not affected (Figure 5A). TNF and CCL3
inductions by ex-polyIC and in-polyIC were relatively
insensitive to IKK-2 inhibitor IV (Figure 5B) although
IL6 and CCL2 inductions by both types of polyIC stimu-
lation were diminished by this inhibitor (Figure 5C).
Differential roles of RELA and RELB in gene expression in
response to extracellular and intracellular polyIC
treatments
As our results suggested that in-polyIC and ex-polyIC
signaling pathways differ in several aspects, we next
assessed whether these two pathways utilize different
NF-kB members for mediating downstream transcrip-
tion regulation. Using siRNA targeting RELA and RELB,
knock-down efficiency of ~92% and ~60%, respectively,
was achieved in HT1080 cells (Figure 6A). Under these
conditions, the induction of IFNB, IL8 and CCL3 in
response to in-polyIC (0.4 μg/ml for 8 h) was dimin-
ished by RELA knock-down but not affected by RELB
knock-down (Figure 6B). Interestingly, while ex-polyIC
stimulation (40 μg/ml for 8 h) was unaffected by RELA
knock-down, the induction of IFNB, TNF and CCL3
was significantly increased by RELB knock-down
(Figure 6C). This experiment was repeated using a sec-
ond set of RELA and RELB siRNAs and yielded similar
results (supplemental data 2).
R E L Bm a yh a v ea ni n h i b i t o r yr o l eo ng e n ei n d u c t i o n s
by ex-polyIC stimulation, while the same inhibitory role
may not be seen in in-polyIC signaling. As a result, the
increase in gene induction by ex-polyIC in the absence
of RELB may also work through the same positive feed-
back mechanism that induced high level of mRNA levels
in in-polyIC signaling. To test this hypothesis, HT1080
cells with RELB knock-down were treated with
ex-polyIC (40 μg/ml for 8 h) in the absence/presence of
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Figure 4 Involvement of TLR3 in gene activation in response
to extracellular and intracellular polyIC treatments. HT1080 cell
line was treated with 40 μg/ml of ex-polyIC and 0.4 μg/ml of in-
polyIC for 8 hours after knocking down TLR3 using gene-specific
siRNA. Control siRNA with random siRNA sequences was included
to monitor non-specific inhibition. Gene expression was measured
using qPCR and the mean from triplicate experiments was
calculated. Error bars represent standard error. A. Nucleofection of
TLR3 siRNA achieved about 75% knock-down efficiency. B. IL8, CCL3
and IFNB inductions in response to ex-polyIC treatment are
dependent on TLR3 whereas the same gene inductions in response
to in-polyIC treatment are independent of TLR3.
Yun et al. BMC Immunology 2011, 12:15
http://www.biomedcentral.com/1471-2172/12/15
Page 6 of 13HsIFNB
Ex-polyIC 4h
Ex-polyIC 8h
In-polyIC 4h
In-polyIC 8h
0
50
100
150
No inhibitor
IKK-2 inhibitor
1000
6000
11000
16000
F
o
l
d
 
I
n
d
u
c
t
i
o
n
HsIL8
Ex-polyIC 4h
Ex-polyIC 8h
In-polyIC 4h
In-polyIC 8h
0
10
20
30
40 No inhibitor
IKK-2 inhibitor
F
o
l
d
 
I
n
d
u
c
t
i
o
n
HsTNF
Ex-polyIC 4h
Ex-polyIC 8h
In-polyIC 4h
In-polyIC 8h
0
4
8
12
No inhibitor
IKK-2 inhibitor
20
60
100
140
F
o
l
d
 
I
n
d
u
c
t
i
o
n
HsCCL3
Ex-polyIC 4h
Ex-polyIC 8h
In-polyIC 4h
In-polyIC 8h
0
10
20
30
No inhibitor
IKK-2 inhibitor
60
70
80
90
F
o
l
d
 
I
n
d
u
c
t
i
o
n
HsIL6
Ex-polyIC 4h
Ex-polyIC 8h
In-polyIC 4h
In-polyIC 8h
0
1
2
3
4
5
6 No inhibitor
IKK-2 inhibitor
F
o
l
d
 
I
n
d
u
c
t
i
o
n
HsCCL2
Ex-polyIC 4h
Ex-polyIC 8h
In-polyIC 4h
In-polyIC 8h
0
2
4
6
8
10
12 No inhibitor
IKK-2 inhibitor
F
o
l
d
 
I
n
d
u
c
t
i
o
n
A
B
C
** ** *
**
*
*
**
**
NS
NS
NS
** **
NS
NS NS
NS
NS
NS
NS
NS NS
NS
NS
Figure 5 Involvement of IKK-2 in gene activation in response to extracellular and intracellular polyIC treatments.H T 1 0 8 0c e l ll i n ew a s
treated with 40 μg/ml of ex-polyIC and 0.4 μg/ml of in-polyIC for 4 and 8 hours in the absence/presence of IKK-2 inhibitor. Gene expression
was measured using qPCR. Graphs show the average of two or three independent experiments, and the student’s t-test was performed to
indicate statistically significant differences between untreated control and IKK-2 inhibitor-treated cells. (* is for P-value≤0.05, ** is for P-value≤0.01
and NS is ‘not significant’.) A. IFNB and IL8 inductions in response to in-polyIC treatment are not significantly affected by IKK-2 inhibition whereas
the same gene inductions in response to ex-polyIC treatment are affected by IKK-2 inhibition. B. TNF and CCL3 inductions in response to both
ex-polyIC and in-polyIC are relatively not affected by IKK-2 inhibition. C. IL6 and CCL2 inductions in response to both ex-polyIC and in-polyIC are
affected by IKK-2 inhibition.
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Figure 6 Involvement of RELA and RELB in gene activation in response to extracellular and intracellular polyIC treatments. HT1080 cell
line was treated with 40 μg/ml of ex-polyIC and 0.4 μg/ml of in-polyIC for 8 hours after knocking down RELA and RELB using gene-specific
siRNAs. Gene expression was measured using qPCR. Graphs show the average of two independent experiments, and the student’s t-test was
performed to indicate statistically significant differences between non-specific siRNA control and gene-specific knock-down cells. (* is for P-
value≤0.05, ** is for P-value≤0.01 and NS is ‘not significant’.) A. Nucleofection of RELA and RELB siRNAs achieved about 92% and 60% knock-
down efficiencies, respectively. B. IFNB, IL8 and CCL3 inductions in response to in-polyIC treatments are dependent on RELA but independent on
RELB. C. IFNB, TNF and CCL3 inductions in response to ex-polyIC treatment are independent of RELA but dependent on RELB. Particularly, IFNB,
TNF and CCL3 inductions in response to ex-polyIC treatment are significantly increased in RELB knock-down. D. HT1080 cell line with RELB-
knocked-down was treated with 40 μg/ml of ex-polyIC in the absence/presence of 10 μg/ml cycloheximide. The increase in gene inductions of
IFNB, TNF and CCL3 is diminished by cycloheximide treatment.
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Page 8 of 1310 μg/ml cycloheximide. Interestingly, the increase in
gene inductions by ex-polyIC previously seen in RELB
knock-down was diminished (Figure 6D). These results
suggest that two types of polyIC stimulation induce
gene expression through differential usage of NF-kB
members RELA and RELB.
Discussion
Recent studies have established there are distinct dsRNA
signaling pathways in innate immunity although the new
intracellular pathways, involving two or possibly more
members of CARD and DExD/H box helicase family,
are not yet extensively mapped out. We have observed
that the gene expression patterns induced by the extra-
cellular and intracellular polyIC are different in HT1080
fibroblast cells, suggesting that at least two distinct
dsRNA signaling pathways may exist (Figure 1). We also
showed that the in-polyIC response is TLR3-indepen-
dent (Figure 4), in concordance with the recent studies.
Our study validated the observations of previous stu-
dies but also revealed novel aspects of the intracellular
dsRNA pathway. First, the substantive induction of
genes by in-polyIC stimulation was diminished when
protein synthesis was blocked using cycloheximide
(Figure 2). We will discuss this finding further in the con-
text of the inhibitory role of RELB in NF-kB signaling
pathways. Secondly, the substantial induction of IFNB by
in-polyIC was shown to have biological significance
demonstrating effective protection against virus chal-
lenges (Figure 3). Thirdly, our results showed that IKK-2
is critical for the expression of NF-kB inducible genes in
both extracellular and intracellular dsRNA pathways.
However, it was also indicated that some NF-kB induci-
ble genes may be activated through IKK-2-independent
mechanism in response to in-polyIC (Figure 5).
Differential utilization of NF-kB members in a number
of different biological systems has been reported. Several
groups have studied the differential usage of NF-kB
RELA and RELB. Earlier studies have observed that the
activation of RELA is inducible whereas RELB is consti-
tutively activated in mouse lymphoid tissues [26-29].
These studies as well as others have shown that RELB is
not inhibited by IkB-1 or IkB-2 [26,29-31]. Furthermore,
subsequent studies using mouse embryonic fibroblast
(MEF) have shown that the activation of RELB is not
through a classical IKK complex containing IKK-2 and
NEMO, but rather through IKK-1 and NIK in several
signaling pathways mediated by lymphotoxinB [32-35],
EBV latent membrane protein 1 [36,37], and RSV [38].
These distinct activation mechanisms are closely linked
to the difference in activation kinetics between RELA
and RELB. Generally, the activation of RELA was shown
to be fast and transient whereas the activation of RELB
tended to be gradual but long-lasting [33,39-42].
Although our study suggests there are both IKK-depen-
dent and -independent mechanisms that mediate
responses to different forms of polyIC stimulation, the
specific molecular mechanisms involved remains to be
understood. Specifically, some possibilities include dif-
ferential activation of the IKK complex or specific regu-
lation of RelA in response to in-polyIC stimulation.
Several mechanisms of regulation regarding RELA
and RELB have been described. The transcription of
RELB could be induced by RELA activation [39], indi-
cating that the activated RELA may contribute to the
latent but enhanced activation of RELB. This fits into
the observation of exchanging dimers, in which the
activation of RELA is quickly down-regulated by the
induction of IkBs but RELB switches with RELA in
gene promoter regions for the prolonged activation of
target genes [41]. Furthermore, even in the absence of
functional RELA, it is shown that RELB may compen-
sate for the loss of RELA in development [43]. On the
other hand, RELB may possess a regulatory effect on
the expression of inflammatory genes. RELB knock-out
mice was reported to generally suffer multi-organ
inflammation [19,20,44,45], and MEF from these mice
showed a persistent induction of several chemokines
[46]. Interestingly, RELB was shown to form an inac-
tive dimer with RELA in TNF-treated MEF [47,48].
This phenomenon was initially understood as RELB
inhibiting activated RELA [48] but later explained that
RELA inhibits RELB to block prolonged RELB-
mediated gene transcription [47].
Our results indicated that RELA may be the major
transcription factor inducing the group of NF-kB regu-
lated genes we tested in both intracellular and extracel-
lular dsRNA signaling pathways. Our preliminary data
showed that ex-polyIC induced nuclear translocation of
RELA at early hours (2 and 4 hour) whereas in-polyIC
induced nuclear translocation of RELA at late hours (8,
10 and 12 hour) (unpublished data). Interestingly, in the
ex-polyIC signaling pathway, our results suggested a
negative regulatory role for RELB had on the induction
of RELA-dependent inflammatory genes (Figure 6). Spe-
cifically, although knock-down of RELB alone was insuf-
ficient for induction of these inflammatory genes, it
provided enhanced expression following ex-polyIC sti-
mulation. We had considered the possibility that the
apparent lack of RELB involvement in in-polyIC signal-
ing may have been due to inefficient knock-down (~60%
for RELB, Figure 6A), but the unexpected enhancement
of ex-polyIC induction of downstream genes suggests in
fact that the RELB knock-down did have some effect on
cellular responses to dsRNA. Conversely, as non-specific
or off-target effects of siRNA treatments are
well-known, these mechanisms may have accounted for
the enhancement of extracellular responsiveness to
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tant lack of enhanced responsiveness to extracellular sig-
naling in other gene-specific-siRNA-treated cells and to
intracellular signaling in the same RELB-siRNA-treated
cells argues against such non-specific effects. Lastly, the
similar results on differential responses to extracellular
and intracellular polyIC provided by a second distinct
RELB-siRNA further supports the specificity of this
observation.
The mechanistic role of RELB in the intracellular
dsRNA signaling is not clear though the translocation of
RELB to nucleus in response to in-polyIC was observed
in HT1080 cells (unpublished data). RELB seems to
neither drive the powerful induction of IFNB and other
inflammatory genes nor to inhibit RELA-mediated gene
transcription in response to in-polyIC (Figure 6). It
would appear that in HT1080 fibroblasts, RELB primar-
ily functions as a negative regulator of transcriptional
activation in response to extracellular dsRNA sensing.
Given its known participation in forming heterodimers
with RELA, some form of squelching may be responsible
for such a negative regulatory role. However, non-
transcriptional mechanisms cannot be ruled out. For
example, RELB may be required for regulating the
expression of a protein that controls mRNA stability. As
genes like IFNB that contain AU-rich elements in their
3’ U T Ra r ek n o w nt ob ea c t i v e l yt a r g e t e df o rm R N A
degradation, the loss of such a function could account
for the enhanced steady-state IFNB levels we observed
in cells with knock-down of RELB. Whether transcrip-
tional or non-transcriptional, the essential role of inhibi-
tory RELB may be to interfere early with the positive
feedback loop created by dsRNA-inducible genes that
are both NF-kB-regulated and NF-kB-activating. Figure
7 illustrates this proposal. In ex-polyIC signaling the
inhibitory RELB may cut off the loop early contributing
to the down-regulation phase, which was observed in
many genes (Figure 1), whereas in in-polyIC signaling or
in RELB-knocked-down ex-polyIC signaling the positive
feedback loop may not be interfered with RELB but can
be diminished by blocking protein synthesis. We would
emphasize that this proposed mechanism may only be
relevant to fibroblasts because other types of cells parti-
cipating in innate immune response (such as macro-
phages and dendritic cells) may utilize these pattern
recognition receptors in different manners. In other
words, RELB may not have any inhibitory role in RELA-
mediated gene responses in these other cell types.
Lastly, other molecules involved in dsRNA signaling,
including IRF3 and MAPK have been observed to exhi-
bit different patterns of activation in response to these
two different types of polyIC stimulation [49]. Therefore,
consistent with our observations of differential activation
of RELA and RELB, the theme of differential activation
of transcription factors by different forms of polyIC sti-
mulation seems generalizable. It would be important to
s t u d yh o wt h e s ea d d i t i o n a lf actors may interact with
RELA and RELB for more complete understanding of
gene regulation in response to extracellular and intracel-
lular polyIC treatments.
Conclusions
Our study shows that the two general categories of
extracellular vs. intracellular dsRNA signaling pathways
may utilize different NF-kB members, and particularly
the differential utilization of RELB may be a key
mechanism to drive powerful inductions of NF-kB regu-
lated genes in the intracellular dsRNA signaling
pathway.
Methods
Cell culture, reagents and polyIC treatment
HT1080 human fibrosarcoma cell line was cultured in
DMEM with 10% fetal bovine serum. IKK-2 inhibitor IV
was added to culture medium at 5 μM concentration
(Calbiochem, EMD Biosciences Inc). Transfection of
polyIC (Amersham Biosciences/GE Healthcare) was per-
formed with FuGENE 6 transfection reagent (Roche
Applied Science) according to the manufacturer’s proto-
col. Cycloheximide (C4859) was purchased from Sigma-
Aldrich Co.
Reverse transcription (RT) reaction and quantitative real-
time PCR (qPCR)
RNA extraction was performed according to the manu-
facturer’s protocol for the RNeasy Kit (QIAGEN).
DNase treatment was performed on RNA samples using
DNA-free (Ambion Inc.) according to the manufac-
turer’s protocol in order to remove genomic DNA con-
tamination. For reverse transcription to generate cDNA,
5 μg of RNA was mixed with RNase-free water (QIA-
GEN) and 1 μlo fo l i g o - d T 23 (Sigma-Aldrich Co.) to a
final volume of 12 μl, then incubated at 90°C for 10
minutes. To this, 4 μl of 5× First-Strand buffer, 2 μlo f
0.1 M DTT, 1 μlo f1 0m Md N T P ,a n d1μl (200 units)
of Superscript II (Invitrogen Co.) were added. The mix-
ture was incubated at 42°C for 90 minutes followed by
15 minutes at 70°C.
qPCR reactions were performed using the ABI Prism
7900HT (PE Applied Biosystem, Perkin Elmer, Foster
City, CA) in 384 micro-well plates. All samples, includ-
ing the external standards and non-template control,
were run in triplicate. The use of external standard and
qPCR condition were previously described [50]. qPCR
was monitored and analyzed by the Sequence Detection
System ver. 2.0 (PE Applied Biosystem, Perkin Elmer,
Foster City, CA). All qPCR primers used in this study
are listed in supplemental data 3.
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All antiviral assays were performed in 96-well plate.
50,000 cells were plated in each well containing 100 μl
of medium and incubated at 37°C overnight before any
treatment. After each treatment, cells were challenged
with EMCV (for 30 hours) or VSV (for 40 hours) at
37°C before staining. Live cells were stained with 0.5%
crystal violet.
siRNA knock-down
All siRNAs (Control - 1022076, TLR3 - SI00050043,
DDX58 - SI00361809, IFIH1 - SI03648981, RELA -
SI00131943 and SI00301672, and RELB - SI00089117
and SI00089131) were purchased from QIAGEN, and
nucleofection was performed using AMAXA Biosystems
according to the manufacturer’s protocol specified as
optimal for HT1080 (Solution V with nucleofection
mode A-23). The efficiency of each gene-specific siRNA
knock-down was calculated based on mRNA levels
measured by quantitative real-time PCR whereby the
percentage represents the resulting mRNA level of each
gene knockdown compared to corresponding control.
Additional material
Additional file 1: 293 cell line treated with ex-polyIC (40 μg/ml) and
in-polyIC (0.4 μg/ml) for 8 h.
Additional file 2: The involvement of RELA and RELB in gene
activation in response to extracellular and intracellular polyIC
treatments. (Second set of siRNAs).
Additional file 3: Real-time PCR primers.
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